Shirley O'Leary, Helen T Brugger, Dale Wallentine, Lisa Sershon, Erica Goff, Toni Saldana-King, Jill Beavin, Robin L Avila, Danette Rutledge, Marie Moore
Natalizumab (TYSABRI®) was the first high-efficacy monoclonal antibody disease-modifying therapy (DMT) approved as a monotherapy for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Because natalizumab is administered by intravenous infusion, infusion nurses play a key role in the care of natalizumab-treated patients. In the 16 years since approval, substantial data have been gathered on the long-term, real-world effectiveness and safety of natalizumab...
November 2023: Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society